MX2014011324A - Metodos para el tratamiento del cancer utilizando inhibidores de la cinasa aurora. - Google Patents

Metodos para el tratamiento del cancer utilizando inhibidores de la cinasa aurora.

Info

Publication number
MX2014011324A
MX2014011324A MX2014011324A MX2014011324A MX2014011324A MX 2014011324 A MX2014011324 A MX 2014011324A MX 2014011324 A MX2014011324 A MX 2014011324A MX 2014011324 A MX2014011324 A MX 2014011324A MX 2014011324 A MX2014011324 A MX 2014011324A
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
kinase inhibitors
aurora kinase
treatment
Prior art date
Application number
MX2014011324A
Other languages
English (en)
Other versions
MX358411B (es
Inventor
Arijit Chakravarty
Jeffrey A Ecsedy
Robert W Kleinfield
Kha N Le
Wen Chyi Shyu
Karthik Venkatakrishnan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2014011324A publication Critical patent/MX2014011324A/es
Publication of MX358411B publication Critical patent/MX358411B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan métodos para el tratamiento de varios trastornos proliferativos de células. En particular, los métodos divulgados para el tratamiento de varios trastornos proliferativos de células mediante la administración de un inhibidor selectivo de la cinasa Aurora A en combinación con quimioterapia a base de taxano, tal como paclitaxel o docetaxel.
MX2014011324A 2012-03-20 2013-03-19 Uso de un inhiboidor de aurora quinasa y paclitaxel para el tratamiento de cáncer de pulmón. MX358411B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014011324A true MX2014011324A (es) 2014-12-05
MX358411B MX358411B (es) 2018-08-20

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011324A MX358411B (es) 2012-03-20 2013-03-19 Uso de un inhiboidor de aurora quinasa y paclitaxel para el tratamiento de cáncer de pulmón.

Country Status (25)

Country Link
US (2) US20130303519A1 (es)
EP (1) EP2827855B1 (es)
JP (1) JP6373252B2 (es)
KR (1) KR102128866B1 (es)
CN (1) CN104271129A (es)
AU (1) AU2013235275B2 (es)
CA (1) CA2868024A1 (es)
EA (1) EA036434B1 (es)
ES (1) ES2746946T3 (es)
GE (1) GEP20186900B (es)
HK (1) HK1206253A1 (es)
IL (1) IL234686B (es)
IN (1) IN2014DN08477A (es)
JO (1) JO3630B1 (es)
MA (1) MA37438A1 (es)
MX (1) MX358411B (es)
MY (1) MY175225A (es)
NZ (1) NZ700744A (es)
PH (1) PH12014502109A1 (es)
SG (2) SG10201607741RA (es)
TN (1) TN2014000387A1 (es)
TW (1) TWI649082B (es)
UA (1) UA117455C2 (es)
WO (1) WO2013142491A1 (es)
ZA (1) ZA201407551B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP6786530B2 (ja) * 2015-07-02 2020-11-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
NL8000715A (nl) 1979-02-07 1980-08-11 Hoffmann La Roche Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten.
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
KR19990087585A (ko) 1996-03-08 1999-12-27 돈 리사 로얄 신경학적 활성제로서의 아졸로벤즈아제핀 유도체
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DK1026167T3 (da) 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
EP1317448B2 (en) 2000-09-15 2011-05-04 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60120219T2 (de) 2000-12-21 2007-04-12 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinase-inhibitoren
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
IL159963A0 (en) 2001-08-09 2004-06-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2554271A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
RS52436B (en) 2004-05-14 2013-02-28 Millennium Pharmaceuticals Inc. UNITS AND PROCEDURES FOR THE INHIBITION OF MITOSIS PROGRESS BY INHIBITION OF AUROR KINASE
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
WO2007080601A1 (en) 2006-01-16 2007-07-19 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
US20070238716A1 (en) 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CN101528237A (zh) 2006-10-31 2009-09-09 艾其林医药公司 艾夫他滨药物组合物
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt) * 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
PH12014502109A1 (en) 2014-12-10
JO3630B1 (ar) 2020-08-27
TW201343169A (zh) 2013-11-01
MY175225A (en) 2020-06-16
NZ700744A (en) 2016-09-30
CA2868024A1 (en) 2013-09-26
US10213436B2 (en) 2019-02-26
MA37438A1 (fr) 2016-05-31
EP2827855B1 (en) 2019-06-26
EP2827855A1 (en) 2015-01-28
ES2746946T3 (es) 2020-03-09
KR102128866B1 (ko) 2020-07-01
JP2015510945A (ja) 2015-04-13
JP6373252B2 (ja) 2018-08-15
SG11201405621UA (en) 2014-10-30
GEP20186900B (en) 2018-10-10
CN104271129A (zh) 2015-01-07
HK1206253A1 (en) 2016-01-08
MX358411B (es) 2018-08-20
KR20140144215A (ko) 2014-12-18
US20160193224A1 (en) 2016-07-07
EA201491727A1 (ru) 2015-01-30
US20130303519A1 (en) 2013-11-14
IN2014DN08477A (es) 2015-05-08
AU2013235275B2 (en) 2017-12-07
UA117455C2 (uk) 2018-08-10
TN2014000387A1 (en) 2015-12-21
SG10201607741RA (en) 2016-11-29
IL234686B (en) 2020-01-30
EA036434B1 (ru) 2020-11-10
TWI649082B (zh) 2019-02-01
IL234686A0 (en) 2014-11-30
AU2013235275A1 (en) 2014-10-23
WO2013142491A1 (en) 2013-09-26
ZA201407551B (en) 2019-01-30

Similar Documents

Publication Publication Date Title
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2020004986A (es) Composiciones mejoradas para tratar distrofia muscular.
MX2015011753A (es) Metodos para tratar cancer de vegija.
PL2922828T3 (pl) Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017012553A (es) Compuestos espirociclicos.
WO2014062878A3 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
MX2015013021A (es) 5-bromo-indirrubinas.
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
WO2016054237A3 (en) Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
MX356102B (es) Compuestos y métodos para tratar leucemia.
WO2014201446A3 (en) Use of hydrogen sulfide synthesis inhibitors for the therapy of colorectal cancers

Legal Events

Date Code Title Description
FG Grant or registration